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ABSTRACT/SUMMARY
Since the early 1950s when sexually transmitted infections (STIs) were first proposed as
a possible risk factor for prostate cancer, numerous epidemiologic studies have been conducted.
Initially, these studies were primarily small case-control studies with retrospective, self-reported
assessment of a narrow range of STIs, typically either any STIs, or gonorrhea and syphilis.
However, as new STIs have been discovered/recognized, new and better tests to detect histories
of STIs have been developed, and new resources for prostate cancer research have been created,
epidemiologic studies have expanded to include a wider range of STIs, and have moved towards
more rigorous, prospective study designs and serologic assessment of STI histories. The results
of these studies are reviewed and discussed, as well as possible new avenues of research, such as
Trichomonas vaginalis infection and infections not typically considered to be sexually
transmitted.
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EARLY HYPOTHESES FOR SEXUALLY TRANSMITTED INFECTIONS AND
PROSTATE CANCER
Early hypotheses related to a sexually transmitted etiology of prostate cancer were
initially motivated by contemporary, epidemiologic patterns of prostate cancer occurrence. In the
early 1950s, Ravich and Ravich [1, 2] noted a higher prostate cancer prevalence among mainly
uncircumcised non-Jewish than circumcised Jewish men, similar to patterns for penile cancer
and cervical cancer among female partners of these men, leading them to propose that observed
patterns might be explained by sexual transmission of a virus or other carcinogenic agent
contained within the smegma of uncircumcised males. Subsequent investigators [3-5] further
proposed additional hypotheses related to infection, sexual behavior, and sexual frustration to
explain other contemporary patterns of prostate cancer occurrence by marital, paternal, and racial
status. Together, these observations and hypotheses led to a series of investigations beginning in
the early 1970s to examine possible associations between STIs and sexual behavior in relation to
prostate cancer.
Selection of STIs
STI markers:
Most early investigations of STIs and prostate cancer assessed either a history of any
STIs or individual histories of gonorrhea and syphilis as markers or possibly vectors of the
potentially causative STI or sexual behavior [6-9]. These STIs were likely selected because they
were the most common, well-known, and symptomatic STIs at the time, making them also more
readily assessed by self-report, medical record abstraction, or registry query.
Prostate inflammation:
Other early studies focused specifically on gonorrhea because it frequently led to
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secondary gonococcal prostatitis in the pre- and early-antibiotic era, and because prostate
inflammation had previously been hypothesized as a cause of atrophy and subsequent prostate
cancer ([9-11] and references therein). This inflammation-atrophy-prostate cancer hypothesis has
since gained further support with the observation of morphological and epigenetic transitions
between areas of inflammation-associated, highly proliferative, atrophic prostatic epithelium,
which have been termed proliferative inflammatory atrophy (PIA) lesions, and areas of highgrade prostatic intraepithelial neoplasia (PIN) and adenocarcinoma. According to this developing
hypothesis, PIA lesions are believed to form as a result of prostate epithelial cell damage and
destruction caused by secretion of oxygen- and nitrogen-based reactive molecules from
inflammatory cells, such as neutrophils and macrophages. Over time, small subsets of cells
within these regenerative lesions are believed to acquire somatic genomic alterations, such as
hypermethylation of the oxygen radical detoxifying glutathione S-transferase P1 gene, making
them more susceptible to genomic damage. This increased susceptibility to genomic damage has
then been postulated to lead to the development of PIN lesions or cancer in the setting of
continued or repeated inflammation and cell injury/death [12].
In addition to proposing gonorrhea as a possible inflammatory cause of prostate cancer,
Wynder and colleagues [10] further proposed that “frequent venereal infections or untreated
chronic venereal infection” might be of interest because these infections were also believed to
contribute to prostatitis; in this case, non-gonococcal prostatitis. Indeed, in the pre- and earlyantibiotic era, prostatitis due to organisms other than Neisseria gonorrhoeae, the causative agent
of gonorrhea, was frequently observed in both men with gonococcal urethritis who may have
acquired additional sexually transmitted organisms at the time of infection with N. gonorrhoeae,
and men with non-gonococcal urethritis [13]. However, no early studies, to our knowledge,
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investigated any of these other common causes of STI-specific prostatitis, possibly because
some, such as Trichomonas vaginalis, were generally less well recognized and less frequently
investigated or diagnosed in men, making them difficult to assess by self-report, while others,
such as Chlamydia trachomatis, had not yet been discovered or recognized as sexually
transmitted pathogens. Therefore, these pathogens would not be investigated in relation to
prostate cancer until several decades later.
Carcinogenic STI therapy:
Rather than focusing on prostate inflammation, Lees and colleagues [14] investigated
syphilis, a very rare cause of granulomatous prostatitis [15], because of the potentially
carcinogenic effects of pre-antibiotic era, parenteral, arsenical therapy for syphilis.
Viral transformation:
Finally, other groups investigated herpesviruses, such as herpes simplex virus type 2
(HSV-2), cytomegalovirus (CMV) and Epstein-Barr virus (EBV), because they: 1) had been
demonstrated to have transforming properties; 2) had been observed in malignant prostate
tissue/cell lines; and 3) were believed to be involved in the development of other cancers, such as
cervical cancer and Burkitt’s lymphoma [8, 16-20]. Primitive serologic tests were available for
these viruses as early as the 1970s, making it possible to assess histories of these infections by
serology rather than or in addition to self-report or medical record abstraction.
Since these early hypotheses were first proposed, several new STIs have been discovered
or recognized, and new and better methods to investigate STI histories have been developed;
however, the rationale behind investigation of these STIs has remained largely the same over the
years, primarily focused on prostate inflammation and viral transformation.
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RESULTS FOR EARLY STUDIES OF STIS AND PROSTATE CANCER
STIs assessed by self-report, medical record abstraction, or registry query:
Considering early studies of STIs and prostate cancer conducted among men more likely
to have been infected in the pre-antibiotic era, several observed suggestive positive associations
for histories of any STIs [6-8, 21] and gonorrhea [9, 11, 17], while others observed null or
suggestive inverse associations for these STIs [10, 14, 22-25] (Table 1). Fewer studies
investigated a history of syphilis in relation to prostate cancer [14, 17, 23], one of which
observed a positive association [14], and the other two observed generally null, unstable results
[17, 23]. With respect to other STIs or symptoms of STIs, one study observed a suggestive
positive association for self-reported history of urethral discharge (possibly indicative of
gonorrhea or another exudative STI) [26], while another observed unstable positive and null
associations for “recurrent genital sores” (possibly indicative of genital herpes) and pediculus
pubis (pubic lice), respectively [17]. Finally, in studies with sufficient numbers of exposed
participants, suggestive positive associations were observed for histories of STIs or STI
symptoms among participants’ female partners, including histories of any STIs [8] and “genital
infection” [26], with prostate cancer among participants. Most other investigations of
participants’ female partners had too few exposed participants to interpret their findings [23-28].
Taken together, these findings suggested that one or more of the more commonly reported STIs,
such as gonorrhea, or another unmeasured or unknown correlated STI, might be associated with
risk of prostate cancer.
Interpretation of study findings:
Information bias:
One concern for interpretation of early study findings is the possibility that many may

6

have been influenced by biases, such as recall and interviewer biases, because most early studies
were case-control in design with retrospective, self-reported assessment of STI histories. This
type of study design and exposure assessment allows for the possibility that participants’
knowledge of their prostate cancer status or awareness of their physicians’ or interviewers’
knowledge of their status may have influenced their responses to study questions, particularly
sensitive questions, such as those related to STI histories. This knowledge may have led prostate
cancer cases to reply more truthfully to questions about STI histories than controls, thereby
possibly leading to a higher reported lifetime prevalence of STIs among cases than controls. In
some early studies of STIs and prostate cancer, interviewers were also likely aware of both
participants’ cancer status and study hypotheses, which may have led them to question prostate
cancer cases more thoroughly for information on STI histories than controls, thereby possibly
further contributing to a higher reported lifetime prevalence of STIs among cases than controls.
Confounding:
Another factor that may have led to false positive associations is the possibility of
confounding by hormone levels, as these may have contributed to both increased sexual activity
and thus increased likelihood of acquiring an STI, as well as increased risk of prostate cancer. To
our knowledge, no early studies were able to address this possible concern, nor did any adjust for
correlates of hormone-associated libido.
Etiologic relevance of the STI exposure:
Although early studies may have been susceptible to information biases and confounding,
and thus to observing false positive associations, they may have also been more likely to capture
STI histories of possibly greater relevance for prostate carcinogenesis than studies that have
since been conducted because early participants were more likely to have passed through
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adolescence and early adulthood (when men typically acquire STIs [29]) before antibiotics had
been developed. During this pre-antibiotic period, 1) some STIs, such as syphilis [30], were more
prevalent and more evenly spread throughout the population (i.e., less restricted to specific
populations), thus increasing the likelihood of infection and repeat infections; 2) several STIs,
such as gonorrhea and syphilis, were more likely to persist because of ineffective treatment; and
3) many STIs were more likely to result in sequela, such as prostatitis or prostatic abscess in the
case of gonorrhea [31]. Therefore, the likelihood of single or multiple episodes of assessed STIs
and co-infections, and their duration and probability of sequela, were likely greater among
participants in earlier that later studies. We have previously hypothesized that these
characteristics may be important for prostate carcinogenesis because each may increase the
chance and/or duration of either asymptomatic or symptomatic prostate involvement. Multiple
episodes of STIs may be more relevant for carcinogenesis than single episodes because of
increased cumulative probability of prostate involvement with each STI episode and increased
cumulative probability of inflammatory immune injury with each episode that involves the
prostate. Infections of longer duration may also be more relevant for carcinogenesis than shorter
infections because of the greater length of time afforded to infectious agents to ascend to the
prostate and the greater potential duration of prostate involvement. Finally, sequela, such as
clinical prostatitis, are relevant to prostate carcinogenesis because they directly represent prostate
involvement and possible inflammatory immune damage to prostate epithelium [32].
Etiologic relevance of the prostate cancer outcome:
A final consideration for interpretation of early study findings for STIs and prostate
cancer is the spectrum of prostate cancer presentation in these studies. All early studies were
conducted before the introduction of prostate specific antigen (PSA) testing for early detection of
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prostate cancer; therefore, these studies may have included a higher proportion of clinically
manifest prostate cancer, such as cancer that was detectable by digital rectal examination or had
progressed to metastases, than later studies. These clinically manifest or life-threatening prostate
tumors may potentially have differing etiology than tumors that never progress to clinicallymanifest disease [33]. Therefore, considering this issue together with all aforementioned issues,
it is difficult to determine the relative contributions of possible biases in study design,
confounding, greater STI exposure, and later prostate cancer presentation to observed findings
from early studies of predominantly self-reported STIs and prostate cancer.
STIs assessed by serology or other laboratory methods:
As mentioned previously, primitive serologic assays were available for several
herpesviruses as early as the 1970s and 80s, allowing for seroepidemiologic investigations of
HSV-2, CMV and EBV infection in relation to prostate cancer. Results from these early studies
were generally mixed; while some observed suggestive positive associations for HSV-2 [17] and
CMV [19] seropositivity, others observed null or suggestive inverse associations for these
viruses and EBV [8, 16] (Table 1). A few additional small studies also investigated herpesvirus
nucleic acids and antigens in prostate tissue with generally unstable results [17, 18, 20].
Interpretation of study findings:
Non-differential exposure misclassification:
Although serologic studies are not susceptible to recall and interviewer biases, exposure
misclassification may still have been introduced into early studies of herpesviruses and prostate
cancer, especially studies of HSV-2, because of the extensive cross-reactivity between HSV-2
antigens and those expressed by the more common HSV-1 [34]. This cross-reactivity may have
led to a considerable number of individual false positive test results and falsely elevated

9

seroprevalences, as evidenced by a comparison of HSV-2 seroprevalences from older studies
(51-66% among controls [16, 17]) and more recent studies (24.3% among men and women 60-69
years of age) [35]. Although this cross-reactivity is unlikely to have been differential by casecontrol status, its considerable extent makes interpretation of study findings difficult.
RESULTS FOR LATER STUDIES OF STIS AND PROSTATE CANCER
STIs assessed by self-report, medical record abstraction, or registry query:
Case-control studies:
Since the first early studies of STIs and prostate cancer were conducted, several
additional case-control studies have investigated possible associations between a history of any
STIs and individual histories of gonorrhea, syphilis, and other STIs typically assessed by selfreport in relation to prostate cancer. Many, but not all [36, 37], of these later studies observed
suggestive positive associations for histories of any STIs [38, 39] and gonorrhea [40-44] where
sufficient numbers of exposed participants existed (Table 2). A few additional studies with much
smaller numbers of exposed participants observed generally unstable estimates [45-48]. For
syphilis, only one case-control study had sufficient numbers of exposed participants to evaluate
its association with prostate cancer; this study observed a positive association for both selfreported and serologically detected history of syphilis [41]. Although unstable, estimates from
the remaining case-control studies of syphilis were also generally supportive of a positive
association when considered together [37, 42-45, 48]. Finally, generally unstable results or no
reported exposure were observed in other studies of genital herpes [37, 42, 43, 45, 49], genital
warts [42, 48, 50], urethritis [42], chancroid [37], “other” STIs [36, 37, 43, 45], and cervical
cancer among participants’ female partners [43, 47]. Thus, similar to earlier case-control studies,
later case-control studies generally observed suggestive positive associations for a history of any
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STIs and individual histories of gonorrhea and possibly syphilis, where sufficient numbers of
exposed participants existed.
Interpretation of study findings:
Etiologic relevance of the STI exposure and prostate cancer outcome:
As compared to participants in earlier case-control studies, those in later studies were less
likely to have passed through adolescence and early adulthood before antibiotics had been
discovered and thus may have been less likely to have ever had an STI, to have had multiple
episodes of STIs or co-infections, or to have had a lengthy duration of infection or sequela than
participants in earlier studies. Indeed, with respect to ever having been infected, self-reported
lifetime prevalences of STIs have generally decreased over time in case-control studies,
particularly those composed predominantly of Caucasian men. Participants in later studies also
typically presented at an earlier stage of prostate cancer than those in earlier studies, which may
have possibly shifted the composition of prostate tumors towards those that may have never
progressed to clinically manifest or life-threatening disease. Both of these factors – lesser
likelihood of extensive STI exposure and earlier prostate cancer presentation – might be
expected to decrease the likelihood of observing true positive associations between STIs and
prostate cancer.
Confounding:
Similar to findings from earlier case-control studies, those from later studies may also
potentially have been influenced by confounding by hormone-associated libido, thereby possibly
leading to false positive associations. However, a few results from later studies suggest this
possibility may be less of a concern. In both positive studies that adjusted for correlates of libido
– sexual activity with prostitutes, number of sexual partners, and frequency of sexual intercourse

11

– similar positive findings were observed as in unadjusted/lesser-adjusted analyses [39, 41],
suggesting that, at least in these two studies, positive results were likely not due to confounding
by hormone-associated libido.
Information bias:
Finally, as compared to earlier studies, later case-control studies may have been less
susceptible to interviewer bias because many assessed STI histories by self-administered
questionnaires and because use of interviewer blinding has likely increased over time. Therefore,
later case-control studies should have been less likely to observe false positive associations due
to interviewer bias than earlier studies. However, one lingering, possible methodologic concern
that may still potentially have contributed to false positive associations in later studies is recall
bias, as all later studies assessed STI histories after prostate cancer diagnosis, and as the STIprostate cancer hypothesis has now been circulating in the medical and lay community for
several decades.
Prospective studies:
To our knowledge, only a few studies have prospectively investigated associations
between gonorrhea, syphilis and prostate cancer to avoid concerns of recall bias. The first two of
these studies were conducted in the 1990s, one of which observed a relatively unstable estimate,
possibly supportive of a positive association, between a history of gonorrhea and risk of prostate
cancer in a nested case-control study [51], while the second observed a significant inverse
association between a history of syphilis and prostate cancer risk in a retrospective cohort study
that compared prostate cancer incidence among cases of syphilis reported to the New York State
Health Department to incidence in the general New York State population [52] (Table 3).
However, this study has been criticized for possible under-ascertainment of prostate cancer cases
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that developed outside of the study catchment area in the syphilis cohort [53]. Indeed, inverse
associations were also observed for colon, rectum, bladder and lung cancer [52], the latter two of
which might be expected to be positively associated with syphilis due to confounding by
smoking, as smoking and STI histories tend to be correlated [54]. Until very recently, these were
the only two prospective studies in the literature. However, more prospective studies are now
beginning to be conducted. In 2006, we published the results of our prospective cohort
investigation in the Health Professionals Follow-up Study (HPFS), in which we observed no
association for a history of gonorrhea and an unstable, null association for a history of syphilis
and risk of prostate cancer [55]. Based on participants’ lower reported lifetime prevalence of
STIs, which we have previously hypothesized also reflects a lower likelihood of repeat and coinfections [32], as well as their education, socio-economic status, and race/ethnicity, we
postulated that histories of gonorrhea and syphilis in this cohort likely reflected only one or two
episodes of treated infection with a low likelihood of co-infections. Therefore, our findings
suggested that low exposure to gonorrhea and syphilis does not increase risk of prostate cancer
[55]. These findings were supported by subsequent results in the Prostate, Lung, Colorectal and
Ovarian (PLCO) Cancer Screening Trial, in which the authors observed no association for a
history of gonorrhea, and an unstable, possibly inverse association for a history of syphilis
among Caucasian participants, who had similarly low reported lifetime prevalences of infection
as HPFS participants. Null or generally unstable results were also observed, however, among
African-American participants in the PLCO Cancer Screening Trial [56] and among Caucasian
and African-American participants in the subsequent California Men’s Health Study [57], all of
whom had considerably higher reported lifetime prevalences of gonorrhea and syphilis than
HPFS or Caucasian PLCO participants. Therefore, these findings suggest that any exposure to
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gonorrhea or syphilis, even more extensive exposure, at least as experienced in the U.S. in the
current antibiotic era, does not increase risk of prostate cancer.
It is possible, however, that other types of infection may increase risk of prostate cancer –
for instance, those more similar to infections experienced in the pre-antibiotic era. This
possibility is suggested by findings from the recent California Men’s Health Study. While no
association was observed for a history of gonorrhea overall in this study population or among
U.S. born Latino men (relative risk (RR)=1.02, 95% confidence interval (CI): 0.63-1.67), a
suggestive positive association was observed among foreign-born Latino men (RR=1.95, 95%
CI: 1.20-3.16), whom the authors hypothesized may have been more likely to have been infected
outside of the U.S., and thus not to have received any or timely treatment. This hypothesized lack
or delay in treatment may have then led to a longer duration of infection, and a possibly greater
likelihood of prostate involvement. A similar, albeit less stable, positive association was also
observed for syphilis among Asian-American men, another more recent immigrant group to the
U.S. [57]. Therefore, although these sub-group findings may have observed by chance, they
leave open the possibility of associations between certain types of STI histories (e.g., untreated
STIs, and those of longer duration) and prostate cancer. Thus, additional prospective studies with
a greater variety of STI exposures may be warranted to elucidate the possible roles of gonorrhea
and syphilis in prostate carcinogenesis.
STIs assessed by serology and other laboratory methods
Since the original hypothesis on STIs and prostate cancer was first proposed, several new
STIs have been discovered or recognized as STIs (e.g., infections by oncogenic HPV types,
human herpesvirus type 8 (HHV-8) and C. trachomatis), and new or considerably better tests to
detect histories of other known STIs have been developed (e.g., HSV-2 and T. vaginalis
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infections). New resources for prostate cancer research have also been created (e.g., cohort
studies with blood collection), allowing for prospective investigations of STIs and prostate
cancer risk, and serologic detection of STI histories, both of which serve to reduce concerns of
recall bias. In general, histories of these newly discovered/recognized STIs are also better
assessed by serology than by self-report because many of these STIs tend to be asymptomatic in
men, and infrequently diagnosed in symptomatic men. Although serology may not capture all
past infections in men, we have previously hypothesized that it may be better at detecting
infections of possibly greater relevance for prostate carcinogenesis, such as repeat infections,
infections of longer duration that might be more likely to ascend to the prostate, and those with
complications, such as prostatitis, because detectable or higher antibody titers have been
observed among individuals with HPV or HHV-8 infections of longer duration; individuals with
Kaposi’s sarcoma, a complication of HHV-8 infection; and women with chlamydial salpingitis, a
complication of C. trachomatis infection (chlamydia), than among individuals with
uncomplicated or transient infections, such as those limited to the lower genitourinary tract [[58]
and references therein]. However, despite its possibly greater sensitivity for etiologically relevant
histories of infection, serology may also falsely identify some men who have never been infected
as seropositive, leading to non-differential misclassification of exposure and a possible bias of
the results towards the null.
Human papillomavirus infection
Of the aforementioned STIs, the first to be extensively investigated in relation to prostate
cancer was HPV infection, particularly types 16 and 18, because of their newly discovered causal
associations with several anogenital cancers, including cervical, penile, and anal carcinomas
[59]. This discovery led to a series of tissue-based and seroepidemiologic investigations of HPV
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infection and prostate cancer beginning in the early 1990s. While the first of these studies
observed suggestive positive findings [60-64], spurring additional research into this field, most
subsequent studies have observed generally null results [[65] and references therein, [56, 58, 6674]]. (Findings from most previous tissue-based studies have been expertly summarized in
Strickler and Goedert’s review article [65]; findings from seroepidemiologic studies are
summarized in Table 4). Initially, investigators proposed that discrepancies between earlier and
later seroepidemiologic findings might be due to differences in the timing of specimen collection
relative to prostate cancer diagnosis, as earlier positive studies collected serum specimens
decades before prostate cancer diagnosis, whereas later null studies generally collected
specimens a few years before or at the time of diagnosis [65]. Therefore, antibody titers could
have possibly waned since an earlier, causative “hit and run” HPV infection or related sexual
factor [65], or during the process of invasive prostate cancer development [66]. However, as null
findings have since been observed in more recent seroepidemiologic studies with early specimen
collection [70, 73], and as minimal/no evidence of high-risk HPV DNA has been observed in
most recent investigations of prostate cancer tissue [68, 69, 72, 75-79], these explanations seem
less likely. Instead, it appears more likely that HPV infection does not influence prostate cancer
risk, at least by biologic mechanisms proposed to date. Therefore, unless new biologic
mechanisms are proposed, or radically new laboratory and/or epidemiologic methods are
developed, further similar investigations are unlikely to yield additional insight.
Human herpesvirus type 8 infection
Although not as extensively studied as HPV infection, HHV-8 infection was also
investigated in relation to prostate cancer because of its recently discovered causal relation with
other cancers, namely Kaposi’s sarcoma and primary effusion lymphoma [80]. Initially, studies
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of HHV-8 infection and prostate cancer observed null associations [81, 82] or detected no
evidence of HHV-8 infection when comparing cancerous to benign prostate tissue [83, 84]
(Table 5). However, in 2004, Hoffman and colleagues [85] observed positive findings between
HHV-8 seropositivity and prostate cancer in a series of case-control comparisons, most notably
one conducted among men of African descent from Tobago, motivating several additional
seroepidemiologic investigations. None of these subsequent investigations have, however,
observed positive findings. Instead, most have observed findings more consistent with a null or
even an inverse association [56, 58, 86, 87], leading the authors of the first positive study to
propose that discrepancies between these null/inverse findings and their positive findings might
be due to chance or possibly to an unknown environmental or genetic difference between
Tobagan men and men from other study countries, as their positive association has reportedly
remained significant after analysis of additional specimens from Tobago [87]. Therefore, more
targeted investigations may be necessary to disentangle these two possibilities, and to explore a
possible inverse association between HHV-8 infection and prostate cancer.
HSV-2, CMV and EBV infections
Although other herpesviruses, such as HSV-2, CMV, and EBV, were first investigated in
relation to prostate cancer as early as the 1970s, only a handful of studies have been conducted
on these viruses to date, most of which were conducted in the last few years after the
introduction of new, considerably less cross-reactive serologic assays for HSV-2. However,
despite use of these new, improved assays, most later studies of HSV-2 [56, 73, 86, 88], CMV
[56, 88] and EBV seropositivity [88] have observed null or generally unstable associations with
prostate cancer (Table 5). One exception to this statement is the recently observed positive
association between HSV-2 seropositivity and prostate cancer risk in a U.S. military study using
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serum specimens collected a mean of 94 months before diagnosis, but not using specimens
collected a mean of 10 months before diagnosis [73]. However, as no association was observed
in the only other study with early specimen collection [86], these findings may have been
observed by chance. Finally, in a later tissue-based study, no association was observed for EBV
DNA positivity, and no evidence of HSV-2 or CMV DNA was detected in prostate tissue [72].
Thus, taken together, findings from these few studies do not support an association between
HSV-2, CMV or EBV infection and risk of prostate cancer. However, it is possible that these
studies could have potentially missed an association if only certain types of herpesvirus
infections, such as those acquired during a critical period of prostate development, are important
for prostate carcinogenesis. In this case, new biomarkers or new types of epidemiologic studies
would be necessary to more fully explore the possible roles of herpesviruses in prostate
carcinogenesis.
Chlamydia trachomatis infection
Another STI that has recently been investigated in relation to prostate cancer risk is
chlamydia, a common bacterial STI. Initially, this STI was included in investigations of prostate
cancer risk as a marker of sexual activity [63]; however, it has since been investigated in relation
to prostate cancer in its own right because of its known ability to cause chronic, persistent
infections, and asymptomatic and symptomatic prostate inflammation in some men [[56, 58, 89]
and references therein]. Despite this promising rationale, most studies to date have observed
generally null or occasionally inverse associations between a history of chlamydia and prostate
cancer, irrespective of the study design, method of assessment (serology or self-report), type of
C. trachomatis antibody assay used (enzyme immunoassay or micro-immunofluorescence
assay), and timing of specimen collection if assessed by serology [42, 56-58, 63, 73, 89] (Table
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5).
A few exceptions to this statement exist. In a recent study conducted in the U.S. military,
a suggestive positive association was observed for C. trachomatis seropositivity using serum
specimens collected at least five years before diagnosis, but not using specimens collected closer
to diagnosis [73]. However, as null or inverse associations were observed in other studies with
early specimen collection [63, 89], this recent sub-group finding may have been observed by
chance. Other possible exceptions include the suggestive positive associations observed for selfreported history of chlamydia and prostate cancer among Asian-American and Latino men in the
California Men’s Health Study [57]. However, these self-reported associations are difficult to
interpret because: 1) they were based on very few exposed cases; 2) chlamydia is frequently
asymptomatic in men and thus difficult to assess by self-report; and 3) chlamydia diagnostics
have only been available since 1985. Therefore, self-reported infections must have been acquired
after 1985 when participants were older and must have been either symptomatic or diagnosed in
participants’ female partners, as men are rarely screened for chlamydia. A final exception to the
overall generally null/inverse findings is the positive association observed for C. trachomatis
IgA seropositivity, a marker of chronic chlamydial infection, among African-American
participants in the PLCO study. However, no association was observed for another marker of
chronic chlamydial infection, C. trachomatis heat shock protein 60 seropositivity [56], raising
the possibility that these findings were observed by chance or that only certain chronic
chlamydial infections (perhaps of a certain duration, or localized to the prostate) are associated
with risk. Therefore, future investigations might benefit from novel biologic markers that can
detect and distinguish between these different types of infection, and from examining men most
likely to have had chronic infections.
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Trichomonas vaginalis infection
Another STI gaining recent attention is Trichomonas vaginalis infection (trichomonosis).
T. vaginalis is a common, sexually transmitted, extracellular protozoan known to cause vaginitis
in 20-50% of infected women and non-gonococcal urethritis and/or prostatitis in a small
percentage of infected men [90, 91]. To our knowledge, T. vaginalis was first proposed as an
infectious agent “of interest” for prostate carcinogenesis by Wynder and colleagues [10],
possibly because of its known ability to cause non-gonococcal prostatitis [13], and its common
occurrence [92]. Gardner and colleagues [93, 94] further contributed to this hypothesis when
they observed inflammatory infiltrates and focal areas of atypical epithelial hyperplasia near T.
vaginalis organisms in prostate tissue from infected men, leading them to propose that T.
vaginalis might contribute to prostate carcinogenesis via an IgE-mediated anti-trichomonad
inflammatory immune mechanism.
Although T. vaginalis is known to cause clinical prostatitis and thus could potentially
contribute to prostate carcinogenesis via symptomatic prostatic inflammation, it was not and still
is not believed to be a major cause of clinical prostatitis. It may, however, be a frequent cause of
asymptomatic prostatic inflammation. We have previously hypothesized that its frequently
asymptomatic or non-specific presentation may allow it to persist undetected and untreated in the
male urethra and thus possibly ascend to the prostate with greater frequency than other more
symptomatic sexually transmitted infectious agents that are now readily detected and treated
(e.g., N. gonorrhoeae) [95]. This hypothesis was based on the pre-antibiotic era observation of a
10-14 day delay between onset of gonorrhea and posterior urethral involvement [96], and the
observed dramatic decline in gonococcal prostatitis following the introduction of antibiotics,
from which we inferred that the longer an infection is left untreated, either due to lack of
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effective treatment or symptoms, the more likely it is to involve the prostate. We further
hypothesized that once/if T. vaginalis reaches the prostate, its frequent lack of symptoms may
also allow it to persist within the prostate, where it may establish a chronic focus of infection
[95]. This hypothesis is supported by findings from early, pre-antibiotic era studies of
trichomonosis in which investigators frequently found evidence of T. vaginalis in prostate
specimens from asymptomatic male partners of women with trichomonal vaginitis [97-102],
some of whom were chronically infected [101].
In addition to eliciting inflammation within the prostate, another possible mechanism by
which T. vaginalis may contribute to carcinogenesis is by directly damaging or lysing prostate
epithelial cells [95]. In in vitro studies, T. vaginalis adherence to host urogenital epithelium has
been observed to lead to epithelial cell death and disruption of epithelial monolayer integrity
[103-106]. Epithelial cells damaged or lysed by T. vaginalis must then be regenerated, allowing
for possible DNA replication errors (particularly if replication occurs in the face of a potentially
genotoxic inflammatory immune response) and hyperproliferation if secretion of growth factors
from inflammatory immune cells becomes dysregulated [95]. T. vaginalis adhesion to urogenital
epithelium has also been observed to upregulate expression of anti-apoptotic genes [107], which
may potentially prevent apoptosis and allow proliferation of prostate epithelial cells damaged but
not lysed by infection. All of these insults - inflammation, cell injury/death and inhibition of
apoptosis - may then potentially lead to the development of PIA lesions [95]. This hypothesis is
supported by Gardner and colleagues’ [93, 94] observation of focal areas of atypical prostatic
epithelial hyperplasia near T. vaginalis organisms and associated inflammatory infiltrates, which,
although not described as such, could possibly represent PIA lesions. Finally, as a further
mechanism by which T. vaginalis may contribute to prostate carcinogenesis, T. vaginalis has
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been observed to alter local polyamine concentrations, which have been found to be related to
prostate cancer in some studies ([95] and references therein).
To our knowledge, trichomonosis was first investigated in relation to prostate cancer in a
small case-control study conducted in the late 1980s, the results of which were largely
inconclusive because none of the participants reported a history of trichomonosis [45]. However,
some participants likely did have a history of trichomonosis: 1) because trichomonosis tends to
be asymptomatic in men and to be treated presumptively rather than specifically diagnosed in
symptomatic men; and 2) because participants reported histories of other more symptomatic,
well-known STIs, such as gonorrhea and syphilis [95]. To our knowledge, no further studies
were conducted on trichomonosis and prostate cancer for almost two decades after this study,
until we conducted a nested case-control study of trichomonosis and prostate cancer risk in the
HPFS, using serology to ascertain a history of trichomonosis. In that study, we observed a
positive association between T. vaginalis serostatus and overall prostate cancer risk (odds ratio
(OR) =1.43, 95% CI: 1.00-2.03), and a suggestion of a more pronounced association for highgrade disease (OR=1.76, 95% CI: 0.97-3.18) [95]. We have since conducted two additional
investigations of trichomonosis and prostate cancer risk, one in the Prostate Cancer Prevention
Trial (PCPT) [108], and the other in the Physician’s Health Study (PHS) [109]. While results in
the PCPT were null, possibly due to the early stage of prostate cancer detected in that trial [108],
results in the PHS were more consistent with our original findings. In that study, we observed a
slight, non-significant positive association between T. vaginalis serostatus and overall prostate
cancer risk (OR=1.23, 95% CI: 0.94-1.61), and significant, considerably more pronounced
positive associations for risks of extraprostatic (OR=2.17, 95% CI: 1.08-4.37) and
metastatic/fatal prostate cancer (OR=2.69, 95% CI: 1.37-5.28) [109]. Thus collectively, findings
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from these initial studies suggest that trichomonosis may be associated with an increased risk of
prostate cancer with the greatest potential for progression to fatal disease. However, additional
investigations of high-grade and advanced stage prostate cancer will be necessary to rule out the
possible role of chance, as well as additional epidemiologic and biologic studies to determine the
validity of this possible association (e.g., studies to investigate possible confounding by other
infectious agents).
CONCLUSION AND FUTURE PERSPECTIVE
Considering the literature on STIs and prostate cancer risk as a whole, particularly studies
less susceptible to biases, a few hints exist to suggest an association between STIs and risk of
prostate cancer. However, this possible association is not clear-cut, and may require more subtle
investigations, both with respect to STI exposure and prostate cancer outcome, to elucidate its
meaning. For instance, many STIs may have the potential to contribute to prostate
carcinogenesis, as many are capable of infecting the prostate and eliciting inflammation or
transforming prostate epithelial cells; however, their likelihood of contributing to prostate cancer
risk may depend on additional characteristics, such as their typical duration of infection,
likelihood of prostate infection, degree of inflammation elicited, degree of epithelial cell damage,
and degree of other infectious agent-specific attribute(s). These characteristics may also vary in
different settings, such as by calendar time (e.g., pre- versus current-antibiotic era), country (e.g.,
countries with access to timely STI treatment versus those without access), race, socio-economic
status, or genetic background. Therefore, these characteristics (e.g., duration of infection) or
markers of these characteristics (e.g., country) may need to be taken into consideration in
interpreting previous study findings and in designing future studies. Future studies of STIs and
prostate cancer would also benefit from the development of new biomarkers, such as those that
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indicate chronicity of infection or prostate involvement.
In addition to considering various aspects of STI exposure, studies of STIs and prostate
cancer may also need to consider aspects of prostate cancer outcome, as STI(s) may not
contribute to risk of all prostate tumors. For instance, STI(s) could possibly contribute to risk of
prostate tumors with the potential to progress to clinically manifest or life-threatening disease,
but not to risk of indolent prostate tumors, such as possibly observed in the case of trichomonosis
[95, 108, 109]. Therefore, prostate cancer characteristics may also need to be taken into
consideration in interpreting previous study findings and in designing future studies.
Although this review has focused on infectious agents with known sexual routes of
transmission, other genitourinary infectious agents not typically considered to be sexually
transmitted may also be important for prostate carcinogenesis – for instance, infectious agents
responsible for bacterial prostatitis. These organisms have been proposed to be sexually
acquired, at least in some instances, based on their detection in the reproductive/genitourinary
tract of both prostatitis patients and their sexual partners [110]. Therefore, these agents may be
potential sexually transmitted infectious candidates for prostate carcinogenesis. New sexually
transmitted infectious agents of possible relevance for prostate cancer are also likely to be
discovered/recognized. For instance, xenotrophic murine leukemia virus-related virus (XMRV),
a recently discovered virus in prostate tissue, has been proposed to be sexually transmitted based
on its increased infectiousness in the presence of semen and its detection in prostate fluid, a
component of semen [111]. This virus was initially identified in prostate tissue from men with
prostate cancer and was found to be considerably more common in men homozygous for the
R462Q variant allele of the ribonuclease L gene, an innate antiviral gene associated with prostate
cancer risk in some studies, than in men carrying non-variant alleles [112]. XMRV has
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subsequently been found to be positively associated with prostate cancer, particularly high grade
prostate cancer, in a study of American men [113], but not in a study of German men [114],
irrespective of R462Q variant status. Therefore, this virus may also be a potential sexually
transmitted infectious candidate for prostate carcinogenesis.
In summary, given the hints of an association between STI(s) and prostate cancer risk
from the literature to date, additional investigations of known, promising STI candidates, such as
trichomonosis, are warranted, as well as investigations of the expanding pool of newly
discovered/recognized STI candidates. However, before beginning these studies, investigators
should carefully consider the relevance of their measured STI exposure (i.e., how likely it is to
capture prostate infection, chronic infections, etc.), the relevance of their prostate cancer
outcome, and the appropriateness of their choice of study population (i.e., how likely the study
population is to have experienced the relevant exposure or outcome of interest), in addition to
typical design considerations (e.g., information biases), to more fully inform possible
associations.
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EXECUTIVE SUMMARY
Early hypotheses for sexually transmitted infections (STIs) and prostate cancer
•

A sexually transmitted etiology for prostate cancer was first proposed by Ravich and Ravich
in the early 1950s to explain the higher observed prevalence of prostate cancer among mainly
uncircumcised non-Jewish than circumcised Jewish men, similar to patterns for penile cancer
and cervical cancer among female partners of these men. This hypothesis, together with other
contemporary observations and hypotheses, led to a series of epidemiologic investigations on
STIs and prostate cancer beginning in the 1970s.

Results for early studies of STIs and prostate cancer
•

Early studies of STIs and prostate cancer (i.e., those conducted in men more likely to have
been infected in the pre-antibiotic era) were primarily small case-control studies with
retrospective, self-reported assessment of a narrow range of STIs, typically either any STIs,
or gonorrhea and syphilis. In general, findings from these studies were supportive of a
positive association between one or more of the more commonly reported STIs and prostate
cancer.

•

Based on their study design and analysis, early studies of STIs and prostate cancer may have
been susceptible to recall bias, interviewer bias, and confounding by hormone-associated
libido, all of which may have possibly led to false positive associations. On the other hand,
greater STI exposure among men who passed through adolescence and early adulthood in the
pre-antibiotic era, and later prostate cancer presentation among men diagnosed before the
introduction of prostate specific antigen (PSA) testing may have possibly contributed to true
positive associations between STIs and prostate cancer. Therefore, it is difficult to determine
the relative contributions of possible biases in study design, confounding, greater STI
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exposure, and later prostate cancer presentation to findings from early studies of STIs and
prostate cancer.
Results for later studies of STIs and prostate cancer
STIs assessed by self-report, medical record abstraction, or registry query
•

Similar to earlier case-control studies, several later case-control studies observed suggestive
positive associations between histories of more commonly reported STIs and prostate cancer.
These positive findings were observed in spite of several differences between earlier and
later studies that might have served to reduce the likelihood of observing both true and false
positive associations: less pre-antibiotic era STI exposure, earlier prostate cancer
presentation, adjustment for correlates of libido, and lesser susceptibility to interviewer bias.
However, one lingering concern for later case-control studies that may still have contributed
to false positive associations is recall bias.

•

Only a few prospective studies have investigated self-reported histories of gonorrhea and
syphilis in relation to risk of prostate cancer to avoid concerns of recall bias. In general, these
studies have observed null associations, although positive findings among foreign-born men
leave open the possibility of associations with specific types of infection (e.g., infections with
a longer duration, untreated infections) less likely to have been observed in American cohort
study populations to date.

STIs assessed by serology and other laboratory methods
•

Since the original hypothesis on STIs and prostate cancer was first proposed, several new
STIs have been discovered or recognized as STIs (e.g., infections by oncogenic human
papillomavirus (HPV) types, human herpesvirus type 8 (HHV-8) and Chlamydia
trachomatis), and new and better tests to detect histories of other known STIs have been
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developed (e.g., herpes simplex virus type 2 (HSV-2) and Trichomonas vaginalis infections).
Several new resources for prostate cancer research have also been created (e.g., cohort
studies with blood collection), allowing for prospective investigations of STIs and prostate
cancer risk, and serologic detection of STI histories, both of which serve to reduce recall
bias.
•

In general, results for HPV, HHV-8, HSV-2, cytomegalovirus, Epstein-Barr virus, and C.
trachomatis infection have been null. However, positive or inverse findings in some
studies/sub-group analyses preclude firm conclusions. Therefore, more subtle investigations
targeted at specific hypotheses (e.g., chronic prostate infections, infection during a critical
period of prostate growth, etc.) may be necessary to elucidate possible associations between
these STIs and prostate cancer.

•

Another STI gaining recent attention is Trichomonas vaginalis infection, a common, but less
well-known, protozoan infection. Results from three seroepidemiologic studies conducted to
date suggest that T. vaginalis infection may be associated with risk of prostate cancer with
the greatest potential to progress to fatal disease. However, additional studies will be
necessary to rule out the possible role of chance, and to investigate the validity of this
possible association.

Conclusion and future perspective
•

Considering the STI and prostate cancer literature as a whole, a few hints exist to suggest that
STIs may contribute to risk of prostate cancer. However, more subtle investigations, both
with respect to STI exposure and prostate cancer outcome, will be necessary to elucidate the
possible role(s) of known, promising STI candidates, as well as the expanding pool of newly
discovered/recognized STI candidates.
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Table 1: Early* case-control studies of sexually transmitted infections (STIs) and prostate cancer
STIs assessed by self-report, medical record abstraction, or registry query
Sample size

Results†

First author, year

Control definition

Steele, 1971 [6]

Hospital
BPH

39

39
35

Self-report

12.8 vs 2.5%
12.8 vs 5.7%

Krain, 1974 [7]

Hospital

221

221

Self-report

28 (12.7‡) vs 5
(2.3%‡), p=0.01

Niijima, 1980 [22]

Hospital

187

200

Medical
record

Mandel, 1987 [8]

Hospital
Population

250

226
240

Self-report

OR=1.89 (0.84-4.24)
OR=1.83 (0.91-3.70)

Ross, 1987 [21]

Black population
White population

142
142

142
142

Self-report

OR=1.7, p=0.03
OR=2.3, p=0.07

Oishi, 1990 [25]

Hospital
BPH

100

100
100

Self-report

OR=0.66 (0.26-1.67)
OR=0.36 (0.16-0.83)

Fincham, 1990
[24]

Population

382

625

Self-report OR=1.02, NS

Black hospital
White hospital

48
251

52
344

Self-report

NA§

NA§

NA§

Registry

Wynder, 1971 [10]
Heshmat, 1973
[11]
Heshmat, 1975 [9]

Baker, 1981 [17]

Mishina, 1985 [23]

Cases Controls

Hospital

BPH

Exposure

Self-report

44

90

Self-report

Population

100

100

Self-report

Lees, 1985 [14]

Hospital
BPH

83

83
83

Medical
record

Feminella, 1975
[27]

BPH

101

101

Medical
record

Any STIs

Gonorrhea

Syphilis

Other STIs

STIs among female partners

NS
Any STIs: OR=2.71 (1.14-6.46)
Any STIs: OR=2.09 (1.02-4.29)

Any STIs: OR=1.81 (0.16-19.9)
Any STIs: OR=1.07 (0.15-7.83)
Cervical cancer: 1 vs 0%, OR=4.94,
NS
26 vs 37%, NS
10 vs 8%, NS
Coherence coefficient
=0.990, p<0.05
25 vs 12 discordant
pairs║, p<0.05
32 vs 22%

5 vs 8%

OR=1.45, χ2=0.59

OR=1.50,
χ2=0.10

OR=0.72, NS
OR=1, NS

OR=2.75, p<0.2
OR=5.5, p<0.05

“Recurrent genital
sores”: 5 vs 0%
Pediculus pubis:
5 vs 7%
Gonorrhea: OR=1.33, χ2=0
Syphilis: OR=5.00, χ2=0.50
Colpitis/vaginitis: OR=1.00, χ2=1.00
Cervical cancer: OR=5.00, χ2=0.50

Cervical cancer:** 3 vs 0%, χ2=3.04,
NS relative to controls
χ2=207, p<<<0.01 relative to U.S.
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population
Greenwald, 1979
[28]

Jackson, 1981 [26]

Widowers who died
of any other cause††
Married men with
any other cancer‡‡

Hospital

151

411

541

497

Cervical cancer:
OR=1.55 (0.65-3.86)
Cervical cancer:
OR=0.35 (0.12-0.98)

Registry

205

205

Urethritis: reported
“more frequently
by [cases] than
controls” OR<2,
p<0.05

Self-report

Genital infection: reported by “more
[cases] than controls”, “definite,
although statistically not significant”
Genital cancer: NS

STIs assessed by serology or other laboratory methods
First author, year

Control definition

Sample size
Cases

Controls

Results†

Exposure

HSV-2

Herbert, 1976 [16]

BPH

28

20

Antibody

Sanford, 1977 [19]

BPH
Bladder cancer
Non-genitourinary cancer

35

23
19
18

Antibody

BPH

50

159

Antigen
Antibody

2 (4.0‡) vs 4 (2.5%‡)
68 vs 51%, p<0.05

Normal
BPH

10

13
9

DNA, RNA or
antigen

2 (20.0‡) vs 1 (7.7%‡)
2 (20.0‡) vs 0 (0.0%‡)

BPH

27

33

Antigen

25.5 vs 24.2%, p>0.8

250

226
240

Antibody

OR=0.27 (0.08-0.98)
OR=0.46 (0.18-1.21)

Baker, 1981 [17]
Boldogh, 1983 [20]
Haid, 1984 [18]
Mandel, 1987 [8]

Hospital
Population

CMV

EBV

71 vs 66%, NS
95, 95, 80 vs 70, 53, 79%§§
95, 95, 80 vs 78, 89, 84%§§
95, 95, 80 vs 61, 78, 55%§§

4 (40.0‡) vs 2 (15.4%‡)
4 (40.0‡) vs 3 (33.3%‡)
OR=1.33 (0.56-3.16)
OR=1.14 (0.41-3.15)

OR=0.50 (0.13-2.00)
OR=0.86 (0.29-2.55)

BPH = benign prostatic hyperplasia; CMV = cytomegalovirus; EBV = Epstein-Barr virus; HSV-2 = herpes simplex virus type 2; OR = odds ratio; NA = not applicable;
NS = not statistically significant.
Early was defined as a mean, median or midpoint age (depending on how the study population was described) of ≥25 years of age as of 1937, the approximate year
when sulphonamide antibiotics were first introduced for treatment of gonorrhea.
† Raw results are provided exactly as described in each manuscript unless otherwise specified. These results are interpreted in the text. In the case in which two
proportions or numbers are presented, the first refers to cases and the second to controls unless otherwise specified.
‡ Derived from data provided in the manuscript.
§ Ecologic study.
║ The first number of pairs refers to discordant pairs in which the case was exposed and the control was unexposed, and the second number of pairs refers to
discordant pairs in which the case was unexposed and the control was exposed.
** Results for cervicitis, vaginitis and syphilis are not presented because the timing of these diagnoses with respect to their husbands’ prostate cancer or BPH
diagnosis is unclear.
†† Cases were widowers who died of prostate cancer.
*

38

‡‡ Cases were married men with prostate cancer.
§§ Three different serologic assays were used.
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Table 2: Later* case-control studies of sexually transmitted infections (STIs) assessed primarily by self-report and prostate cancer
Sample size
First author, year

Results†

Control definition
Cases

Controls

Exposure

Any STIs

Gonorrhea

Hayes, 1992 [46]

Hospital

100

113

Self-report NS (low prevalence)

Ewings, 1996 [47]

Hospital and BPH

159

325

Self-report OR=2.06 (0.38-11.22)
Self-report OR=2.12 (1.27-3.53)

Lightfoot, 2004 [38]

Syphilis

Population

760

1,632

Hospital

273

254

Self-report OR=1.7 (1.1-2.5)

Checkoway, 1987
[45]

BPH

40

64

Self-report

10.0 vs 7.8%

5.0 vs 4.7%

Honda, 1988 [44]

Population

216

216

Self-report

OR=1.4 (0.8-2.6)

OR=6.0 (0.7-276.0)

Ilic, 1996 [40]

Hospital

101

202

Self-report

4.0 vs 0.0%, p>0.10§

Hsieh, 1999 [36]

Hospital

320

246

Self-report

χ for contrast or
trend=0.73, p=0.47

Black population

479

594

White population

502

721

Hayes, 2000 [41]

Rosenblatt, 2001
[42]

Population

Black population

753

353

703

Self-report

257

Patel, 2005 [37]

OR=1.6 (1.2-2.2)
OR=1.4 (0.7-2.9)

OR=1.50 (1.02-2.18)

OR=1.0 (0.7-1.6)
Self-report

White population

347

347

STIs among female
partners
Cervical cancer:
OR=0.56 (0.06-2.98)

Fernandez, 2004
[39]

Self-report
Antibody
Self-report
Antibody

Other STIs

OR=1.1 (0.5-2.5)

40

Genital herpes: 0.0 vs
0.0%‡
Other STI: 0.0 vs 0.0%

Other STI: χ for
contrast or trend=
-0.31, p=0.76
OR=2.4 (1.2-4.9)
OR=2.2 (1.0-4.6)║
OR=2.8 (0.2-49.1)
OR=0.8 (0.2-3.5)║

OR=1.60 (0.51-5.02)

Urethritis: OR=0.80
(0.38-1.68)
Genital herpes:
OR=1.65 (0.69-3.99)
Genital warts:
OR=0.88 (0.38-2.08)
**

Genital herpes: Could
not be estimated
Chancroid: OR=0.2
OR=1.3 (0.5-3.2)
(0.02-1.9)
Other STIs: OR=1.8
(0.3-9.6)
Could not be estimated Genital herpes:
OR=1.2 (0.3-5.5)
Chancroid: OR=0.8
(0.05-13.0)

Other STIs: OR=0.7
(0.1-3.9)
Pelucchi, 2006 [48]
and La Vecchia,
1993 [49]

Hospital

280

689

Sarma, 2006 [43]

Population

129

703

Newell, 1989 [50]

Other cancer

110

220

Self-report

OR=0.64 (0.20-2.03)

Self-report

OR=1.78 (1.13-2.79)

Genital herpes: NS
(low number exposed)
OR=1.75 (0.10-31.44)
Genital warts: Could
not be estimated
OR=1.54 (0.55-4.34)

Herpes: OR=0.89
(0.11-7.70)
Other STIs: OR=1.12
(0.23-5.47)

Cervical cancer:
OR=2.06 (0.41-10.45)

Genital warts: NS

BPH = benign prostatic hyperplasia; OR = odds ratio; NS = not statistically significant.
*

Later was defined as a mean, median or midpoint age (depending on how the study population was described) of <25 years of age as of 1937, the approximate year
when sulphonamide antibiotics were first introduced for treatment of gonorrhea.
† Raw results are provided exactly as described in each manuscript unless otherwise specified. These results are interpreted in the text. In the case in which two
proportions or numbers are presented, the first refers to cases and the second to controls unless otherwise specified.
‡ Results for Trichomonas vaginalis infection are described later in the text in the section on T. vaginalis infection.
§ Recalculated using Fisher’s exact test as p=0.01.
║ Serologic testing was performed on a subset of the study population: 125 Black cases, 131 Black controls, 146 White cases and 155 White controls.
** Results for Chlamydia trachomatis infection are described later in Table 5.
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Table 3: Prospective studies of sexually transmitted infections (STIs) assessed by self-report, medical record abstraction, or registry query and prostate cancer
First author, year

Study design

Sample size

Results*

Exposure
Gonorrhea

Hiatt, 1994 [51]

Syphilis

Nested case-control

238 cases, 238 controls

Michalek, 1994 [52]

Cohort

Approximately 10,262 exposed†

Registry

Sutcliffe, 2006 [55]

Cohort

32,932

Self-report

RR=1.04 (0.79-1.36)

RR=1.06 (0.44-2.59)

Self-report

OR=1.0 (0.6-1.6)
OR=1.4 (0.8-2.2)
RR=0.9 (0.6-1.4)
RR=1.0 (0.8-1.3)

OR=0.8 (0.3-2.4)
OR=0.4 (0.1-1.9)
RR=0.7 (0.3-1.8)
RR=0.4 (0.1-1.3)

Black: 5,784

RR=1.12 (0.88-1.44)

RR=1.32 (0.80-2.17)

White: 42,409

RR=0.94 (0.78-1.14)

RR=0.93 (0.54-1.61)

RR=1.16 (0.56-2.41)

RR=3.72 (1.35-10.26)

Latino: 11,213

RR=1.39 (1.01-1.91)

RR=1.38 (0.64-2.93)

Other: 3,245

RR=1.43 (0.70-2.92)

RR=0.91 (0.12-6.66)

Nested case-control
Huang, 2008 [56]
Cohort

Cheng, 2010 [57]

Cohort

Other STIs

Medical record OR=1.5 (0.5-4.2)

Black: 103 cases, 368 controls
White: 765 cases, 915 controls
Black: 1,516‡
White: 29,995‡

Asian: 6,024

Self-report

SIR=58 (37-86)

Genital herpes:
Genital warts:
Genital herpes:
Genital warts:
Genital herpes:
Genital warts:
Genital herpes:
Genital warts:
Genital herpes:
Genital warts:

OR = odds ratio; RR = relative risk; SIR = standardized incidence ratio.
*
†
‡
§

Raw results are provided exactly as described in each manuscript unless otherwise specified. These results are interpreted in the text.
Derived from data provided in the manuscript.
Provided by authors.
Results for Chlamydia trachomatis infection are described later in Table 5.
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RR=0.91 (0.57-1.46)
RR=0.55 (0.28-1.07)§
RR=0.78 (0.58-1.06)
RR=0.93 (0.70-1.25)§
RR=1.20 (0.38-3.81)
RR=Could not be estimated§
RR=1.16 (0.63-2.13)
RR=0.44 (0.16-1.19)§
RR=0.75 (0.10-5.54)
RR=0.58 (0.08-4.25)§

Table 4: Seroepidemiologic studies of human papillomavirus (HPV) infection and prostate cancer
First author, year

Study design

Result*

Sample size
HPV-16

HPV-18

p=0.54 for geometric mean
comparison
1.6 vs 4.9%, p=0.44

Other HPV types
HPV-11: p=0.64 for geometric mean
comparison

Strickler, 1998 [115]

Case-control

63 cases, 144 BPH controls

Strickler, 1998 [116]

Case-control

47 cases, 48 endocrine disorder
controls

Dillner, 1998 [63]

Nested case-control

165 cases, 290 controls

Hisada, 2000 [64]

Nested case-control

48 cases, 63 controls

Rosenblatt, 2003
[66]

Case-control

642 cases, 570 population controls OR=1.06 (0.71-1.57)

OR=1.36 (0.69-2.69)

Adami, 2003 [67]

Case-control

238 cases, 210 population controls OR=0.7 (0.4-1.3)

OR=0.9 (0.5-1.9)

HPV-33: OR=1.6 (1.0-2.7)

OR=0.55 (0.19-1.60)
OR=2.00 (0.37-10.92)
OR=0.81 (0.47-1.40)
OR=0.79 (0.49-1.26)

HPV-33: OR=1.04 (0.45-2.44)
HPV-33: OR=0.89 (0.36-2.22)
HPV-33: OR=1.00 (0.69-1.47)
HPV-33: OR=0.99 (0.72-1.38)

OR=0.83 (0.57-1.23)

OR=1.04 (0.66-1.64)

HPV-33: OR=1.14 (0.76-1.72)

OR=1.0 (0.7-1.6)
OR=0.9 (0.7-1.3)

OR=0.9 (0.6-1.5)
OR=1.2 (0.8-1.7)

Korodi, 2005 [70]

Finland: 136 cases, 498 controls
Sweden: 87 cases, 346 controls
Nested case-control
Norway: 577 cases, 1,752 controls
Total: 800 cases, 2,596 controls
Case-control

205 cases, 673 other cancer and
cardiovascular disease controls

Sutcliffe, 2007 [58]

Nested case-control

691 cases, 691 controls

Huang, 2008 [56]

Nested case-control

Black: 103 cases, 368 controls
White: 765 cases, 915 controls

Dennis, 2009 [73]

Nested case-control

267 cases, 267 controls

Sitas, 2007 [71]

Sutcliffe, 2010 [74]

Nested case-control

6 vs 4%
OR=2.58 (0.77-8.56)

OR=2.88 (1.27-6.56)

HPV-33: OR=0.66 (0.26-1.66)†
HPV-11: OR=0.61 (0.27-1.39)†

OR=2.7 (0.9-7.9)

OR=0.44 (0.15-1.26)
OR=1.18 (0.53-2.66)
OR=0.97 (0.64-1.46)
OR=0.90 (0.64-1.26)
Medium:‡ OR=1.33 (0.87-2.04)
High:‡ OR=1.22 (0.77-1.93)

Mean 10 mo§, HPV-16 or -18: OR=0.92 (0.59-1.45), HPV-16,-18,-6 or -11: OR=1.07 (0.75-1.52)
Mean 94 mo§, HPV-16 or -18: OR=1.13 (0.73-1.75), HPV-16,-18,-6 or -11: OR=0.98 (0.69-1.40)
>60 mo§,
HPV-16 or -18: OR=1.20 (0.74-1.95), HPV-16,-18,-6 or -11: OR=1.00 (0.67-1.50)
Weak:‡ OR=0.94 (0.53-1.64)

Weak:‡ OR=0.75 (0.27-2.04)

Strong:‡ OR=1.07 (0.77-1.48)

Strong:‡ OR=0.87 (0.47-1.63)

616 cases, 616 controls

HPV-31, weak:‡
OR=0.76 (0.45-1.28)
HPV-31, strong:‡
OR=1.15 (0.80-1.64)

BPH = benign prostatic hyperplasia; OR = odds ratio.
*
†
‡
§

Raw results are provided exactly as described in each manuscript unless otherwise specified. These results are interpreted in the text. In the case in which two
proportions or numbers are presented, the first refers to cases and the second to controls unless otherwise specified.
Crude OR. Other ORs presented for Diller, 1998 [63] are adjusted.
Seropositivity.
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Table 5: Later* case-control studies of other sexually transmitted infections (STIs) typically assessed by serology or other laboratory methods and prostate cancer
Result†

First author, year

Study design

Sample size

Exposure

Monini, 1996 [81]

Case-control

8 cases, 8 BPH controls

DNA

25 vs 63%

Tasaka, 1997 [83]

Case-control

32 cases, 20 BPH controls

DNA

No DNA detected

Lebbe, 1997 [84]

Case-control

6 cases, 13 BPH controls, 3 normal
controls

DNA

No DNA detected

Sitas, 1999 [82]

Cross-sectional
survey of cancer
patients

3,293 patients (202 prostate cancer,
3,091 other cancer)

Case-control

Caribbean:
138 Tobago cases, 140 Tobago controls
174 Trinidad controls
United States:
100 cases, 99 other cancer controls
177 blood donor controls

HHV-8

Hoffman, 2004 [85]

Korodi, 2005 [86]

Nested case-control

163 cases, 288 controls

HSV-2, CMV or EBV

C. trachomatis

Antibody NS

Antibody

OR=2.24 (1.29-3.90)
OR=2.63 (1.54-4.50)
OR=1.65 (0.77-3.54)
OR=4.67 (1.9-11.65)

Antibody OR=0.74 (0.19-2.88)

HSV-2: OR=0.93 (0.44-1.96)

Lytic IFA: OR=1.08 (0.27-4.33)
K8.1 ELISA: OR=0.813 (0.17-4.21)
ORF73 ELISA: OR=0.60 (0.12-3.03)

Italy:
10 cases, 34 BPH controls
United States:

Lytic IFA: OR=0.88 (0.35-2.24)
K8.1 ELISA: OR=0.328 (0.10-1.11)
Antibody ORF73 ELISA: OR=0.43 (0.16-1.18)
Lytic IFA: OR=0.56 (0.28-1.14)
Black: 95 cases, 75 population controls
K8.1 ELISA: OR=0.52 (0.10-2.66)
ORF73 ELISA: OR=0.62 (0.17-2.20)
Lytic IFA: OR=0.71 (0.36-1.43)
White: 104 cases, 80 population controls
K8.1 ELISA: OR=0.76 (0.17-3.40)
ORF73 ELISA: OR=0.77 (0.13-4.44)
Black: 41 cases, 98 BPH controls

Jenkins, 2007 [87]

Case-control

Sutcliffe, 2007 [58]

Nested case-control

691 cases, 691 controls

Antibody OR=0.70 (0.52-0.95)

Black: 103 cases, 368 controls
Huang, 2008 [56]

Nested case-control

OR=0.3 (0.1-1.4)
Antibody

White: 765 cases, 915 controls
Berrington de
Gonzalez, 2006 [88]
Bergh, 2007 [72]

OR=1.3 (0.9-1.7)

Case-control

66 cases, 95 other cancer controls, 101
cardiovascular disease controls

Antibody

Nested case-control

159 cases, 159 controls

DNA

OR=1.13 (0.65-1.96)
HSV-2: OR=1.3 (0.8-2.0)
CMV: OR=0.9 (0.4-1.7)
HSV-2: OR=0.9 (0.7-1.3)
CMV: OR=1.1 (0.9-1.3)
HSV-2: NS
CMV: NS
HSV-2: No DNA detected
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IgG: OR=1.1 (0.7-1.7)
IgA: OR=2.1 (1.2-3.6)
IgG: OR=1.2 (0.9-1.6)
IgA: OR=0.7 (0.4-1.1)

CMV: No DNA detected
EBV: 9.4 vs 8.8%
HSV-2, mean 10 mo‡:
OR=1.17 (0.79-1.73)
HSV-2, mean 94 mo‡:
OR=1.60 (1.05-2.44)
HSV-2, >60 mo‡:
OR=2.04 (1.26-3.29)

Mean 10 mo‡:
OR=1.07 (0.64-1.81)
Mean 94 mo‡:
OR=1.35 (0.79-2.31)
>60 mo‡:
OR=1.80 (0.96-3.38)

Dennis, 2009 [73]

Nested case-control

267 cases, 267 controls

Antibody

Dillner, 1998 [63]

Nested case-control

165 cases, 290 controls

Antibody

OR=1.04 (0.54-2.00)

Rosenblatt, 2001
[42]

Case-control

753 cases, 703 population controls

Self-report

OR=0.43 (0.12-1.48)

Nested case-control

Finland: 138 cases, 497 controls
Sweden: 86 cases, 341 controls
Norway: 514 cases, 1,433 controls
Total: 738 cases, 2,271 controls

Antibody

OR=0.71 (0.40-1.29)
OR=0.52 (0.15-1.79)
OR=0.70 (0.48-1.03)
OR=0.69 (0.51-0.94)

Cohort

Black: 5,784
White: 42,409
Asian: 6,024
Latino: 11,213
Other: 3,245

Self-report

RR=1.00 (0.62-1.63)
RR=0.88 (0.59-1.32)
RR=5.55 (1.70 -18.09)
RR=1.82 (0.80-4.15)
RR=1.39 (0.19-0.18)

Anttila, 2005 [89]

Cheng, 2010 [57]

BPH = benign prostatic hyperplasia; CMV = cytomegalovirus; EBV = Epstein-Barr virus; ELISA = enzyme-linked immunosorbent assay; HSV-2 = herpes simplex virus type
2; HHV-8 = human herpesvirus type 8; OR = odds ratio; IFA = immunofluorescence assay; NS = not statistically significant; RR = relative risk.
*
†
‡

Later was defined as a mean, median or midpoint age (depending on how the study population was described) of <25 years of age as of 1937, the approximate year when
sulphonamide antibiotics were first introduced for treatment of gonorrhea.
Raw results are provided exactly as described in each manuscript unless otherwise specified. These results are interpreted in the text. In the case in which two proportions
or numbers are presented, the first refers to cases and the second to controls unless otherwise specified.
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